drugset / Trial / NCT03368963
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Phase 1/2
Active not recruiting
64 enrolled
Emory University
Ipsen · collabTaiho Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2018-01-30
- Primary completion
- 2025-06-28
- Completion
- 2025-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Tipiracil | Small molecule | — | Oral |
| Subject | Trifluridine | Small molecule | — | Oral |